2017-03-24 Hoersholm, Denmark, March 24th, 2017 - Medical Prognosis Institute A/S (MPI.ST) (Denmark and Phoenix, AZ, USA) today announced that Oncology Venture have entered an agreement with Eisai Inc. (Woodcliff Lake, NJ, USA) under which Oncology Venture will develop a Companion Diagnostic utilizing MPI`s Drug Response Predictor, DRP(TM) technology for an undisclosed Eisai oncology therapeutic agent in order to evaluate its interest in in-licensing the drug for further clinical development in the OV spin-out, 2X Oncology Inc. (Boston, MA USA). The agreement does not imply costs for MPI. If the DRP(TM) evaluation is successful, OV may exclusively in-license the drug for further development...
|